Entyvio Newsroom

On this page you will find the latest press releases and relevant news about Entyvio. You can request additional information on Entyvio here.

May 19, 2015
12 abstract presentations highlight Vedolizumab efficacy and safety data

February 20, 2015
Takeda Presents Vedolizumab Data at European Crohn’s and Colitis Organisation Congress

September, 2014
Takeda Presents New Interim Phase 3 Maintenance Data that Support the Long-Term Efficacy of Vedolizumab in Patients with Ulcerative Colitis and Crohn’s Disease

May 27, 2014
Takeda Receives European Commission Marketing Authorisation for Entyvio® (vedolizumab) for the Treatment of Ulcerative Colitis and Crohn’s Disease

March 21, 2014
Takeda Receives Positive CHMP Opinion for Entyvio® (vedolizumab) in Europe for the Treatment of Ulcerative Colitis and Crohn's Disease

August 21, 2013
Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohn's Disease

March 7, 2013
Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohn's Disease in the European

May 11, 2012 
Takeda Announces GEMINI II Trial of Vedolizumab in Patients with Moderately to Severely Active Crohn’s Disease Met Primary Endpoints of Improvement in Clinical Remission in Induction and Maintenance Phases

February 12, 2012
Takeda Announces Primary Endpoints Met for Pivotal Phase 3 Trial of VEDOLIZUMAB in Patients with Moderately to Severely Active Ulcerative Colitis Who Have Failed at Least One Conventional Therapy -GEMINI I Trial Met Primary Endpoints of Improvements in Clinical Response in Induction and Clinical Remission in Maintenance